NeuroSense Therapeutics Ltd.

www.neurosense-tx.com

High-Tech Company
Public Company

(NASDAQ CM: NRSN)

TECH VERTICALS

ALS, Biopharmaceuticals, Biotechnology, Life Sciences, MedTech, Therapeutics

General Data

Sector	Biomed
Company Stage:	R&D
Established	2016
Number of Employees	30
Employees in Israel	20
Reg. Number:	abCDe

DESCRIPTION

NeuroSense is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. NeuroSense believes that these diseases, which include amyotrophic lateral sclerosis (ALS), Alzheimer's disease and Parkinson's disease, among others, represent one of the most significant unmet medical needs of our time, with limited effective therapeutic options available for patients to date. Due to the complexity of neurodegenerative diseases and based on strong scientific research on a large panel of related biomarkers, NeuroSense's strategy is to develop combined therapies targeting multiple pathways associated with these diseases.

TECHNOLOGY

Multi-target combination therapeutics for neurodegenerative diseases (ALS-focused).

Products and Phases

Product	Phase
StabiliC	Phase I
A drug for Parkinson’s based on the foundations of PrimeC for ALS. Pre-clinical trails tested StabiliC in in-vivo models of Parkinson’s, assessing morphological and functional effects, exploring potential co-development with collaborators that have core focus in Parkinsons.
CogniC	Phase II
A drug for Alzheimer’s based on the foundations of PrimeC. NeuroSense has initiated the pre-clinical stage, testing CogniC in in-vitro models representing Alzheimer’s disease pathologies, and now initiating a phase 2 double blind placebo controlled study with 20 AD patients.
PrimeC	Phase III
NeuroSense’s novel drug, PrimeC, aims to treat ALS by regulating microRNA synthesis, reducing neuroinflammation, and influencing iron accumulation. PrimeC is a novel formulation composed of unique doses of two FDA-approved drugs, Ciprofloxacin and Celecoxib, which aim to synergistically inhibit the progression of ALS. The drug mitigates the degeneration and inflammatory response of motor neurons, and has significantly outperformed conventional treatments in a zebrafish model of ALS.

	TARGET MARKETS
	Pharmaceutical companies, Healthcare systems; Neurodegenerative disease patients, such as ALS, Alzheimer's disease and Parkinson's.

	BUSINESS MODEL
	B2B

Patents

Expand / Collapse All

Publication ID/Number

Patent Title

Status

Initial Filing Date

US20240325352

Compositions Comprising an Anti-Inflammatory Drug and a Dicer Activator for use in the Treatment of Neuronal Diseases

Granted

Jun. 20, 2018

Grant Date	Jan. 20, 2026
Jurisdictional Coverage	US
Technology Classification	A61K 31/416, A61K 31/415, A61K 31/496, A61P 25/00
Description	The present invention discloses compositions, means and kits thereof for treating neuronal clinical indications in a mammalian subject. The composition comprises, inter alia, a synergistic combination of an anti-inflammatory drug and a DICER activator. The present invention further discloses methods for treating neuronal diseases including Motor neuron diseases (MNDs), ALS, FTD (Frontotemporal Dementia), macular degeneration (AMD) autism, and neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease.
Expiration Date
Publication Date	Oct. 03, 2024
Rejection Date
Web Link	https://patentscope.wipo.int/search/en/detail.jsf?docId=US440284056&_cid=P10-MKTROY-28875-1
Remarks

CONTACT INFO

Expand / Collapse All

Main Address: Herzliya, Israel

Address	11 Ha-Menofim St.
City	Herzliya
Country	Israel
Zip	4672562

Contact Person	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

Branch Address: Cambridge, United States

Address	1 Broadway
City	Cambridge
State/Province	MA
Country	United States
Zip	02142

Contact Person	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

	MANAGEMENT

Key Executive

Name	Title	Previous Position
Mr. Alon Ben-Noon	CEO & Co-Founder	Nano Dimension (Business Development Director)
Dr. Ferenc Tracik	Chief Medical Officer
Mr. Or Eisenberg	CFO	Katzir (Controller)
Dr. Niva Russek-Blum	CTO
Ms. Hagit Binder	COO	Nextar (VP, Projects & Marketing)
Dr. Sharon Cohen-Vered	VP, CMC	NeuroDerm (a Mitsubishi Tanabe Group Company) (Head of CMC)
Ms. Nedira Salzman-Frenkel	VP, Business Development
Dr. Shiran Zimri	VP, R&D
Ms. Keren Pushett	Head of HR
Mr. Ariel Gordon	Co-Founder	ServiceNow Israel (VP, Product Management)
Prof. Eran Hornstein	Inventor & Co-Founder

	BOARD

Board

Member	Title	Affiliation
abC Defghij	Chairman	CEO, SpyBiotech
abC Defghij	Board Member	Board Director, Tempest Therapeutics
abC Defghij	Board Member	CEO, Prosperity Capital Management, LLC
abC Defghij	Board Member	CEO & Co-Founder, NanoCarry
abC Defghij	Board Member	CEO & Co-Founder, Neurosence
abC Defghij	Board Member	Former CFO, Ayala Pharmaceuticals

Public Offerings

Deal Date	Type of Offering	Exchange	Amount Raise	Valuation	Remarks
Dec. 13, 2021	IPO	NASDAQ CM	abCDe	abCDe

	FINANCIAL ROUNDS

Total Capital Raised
abCDe

Financial Rounds

Numbers of Investors

Expand / Collapse All

Round

Date

Stage

Amount

Valuation

PIPE

Dec. 02, 2024

R&D

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe

First Round - Extended

Apr. 26, 2020

R&D

abCDe

First Round

Jul. 12, 2019

R&D

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Investment Company	abCDe
abC Defghij	Angel Syndicate	abCDe	Private Investors via PipleBiz equity crowdfunding platform.
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe

Seed

Oct. 01, 2016

Seed

abCDe

	R&D Grants

Expand / Collapse All

Round

Date

Stage

Amount

Remarks

R&D Grant

Mar. 08, 2017

R&D

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Government Agency	abCDe

	Non-Equity Assistance

Expand / Collapse All

Date

Stage

Remarks

Non-Equity Assistance

Oct. 18, 2016

R&D

Contributor	Type	Amount	Remarks
abC Defghij	General Accelerator	abCDe

Last Updated:	abCDe
IVC Number:	abCDe